Cytokeratin 7 Antibody [H19A10] | Primary Antibodies

Application: Reactivity: Human

Usage Information

Dilution
WB1:5000 - 1:10000 IP1:20 - 1:30 IHC1:1000 IF1:100 - 1:250 FCM1:20 - 1:30

Application
WB, IP, IHC, IF, FCM

Reactivity
Human

Source
Rabbit Monoclonal Antibody

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW Observed MW
51 kDa 51 kDa
^*Why do the predicted and actual molecular weights differ? The following reasons may explain differences between the predicted and actual protein molecular weight.

Positive Control	Human breast carcinoma tissue; Human urinary bladder transitional carcinoma tissue; Human bladder carcinoma tissue; Human colonic adenocarcinoma tissue; Human endometrial carcinoma tissue; Human ovarian carcinoma tissue; T47D cells; HeLa cells; SK-OV-3 cells; A549 cells
Negative Control	Human sarcoma tissue; MCF7 cells

Datasheet & SDS

Biological Description

Specificity
Cytokeratin 7 Antibody [H19A10] detects endogenous levels of total Cytokeratin 7 protein.

Clone
H19A10

Synonym(s)
SCL; KRT7; Cytokeratin-7; Keratin-7; Sarcolectin; Type-II keratin Kb7; CK-7; K7

Background
Cytokeratin 7, or CK7, is a type II intermediate filament protein encoded by the KRT7 gene on chromosome 12q12-13. It forms heterotypic pairs with type I keratins such as CK19 to build the cytoskeletal framework vital for maintaining structural integrity in epithelial cells, especially within simple glandular epithelia lining organs like the lung, breast, ovary, biliary tract, pancreas, urothelium, and the ducts and blood vessels of the female genital tract. CK7 features a central alpha-helical rod domain of 310 to 350 amino acids, which shares about 50 to 90 percent sequence identity with other type II keratins and contains four heptad-repeat segments (1A, 1B, 2A, 2B) necessary for coiled-coil dimerization. This rod is flanked by non-helical N-terminal and C-terminal head and tail domains that include V1 and V2 subdomains rich in glycine and serine, contributing to its insolubility and molecular interactions, and conserved H1 and H2 motifs typical of type II chains, enabling the formation of tetramers that further assemble into 10 nm intermediate filaments providing mechanical resilience. CK7 maintain cytoplasmic architecture and withstands mechanical stress in ductal epithelia, while also facilitating cell differentiation, polarity, and tissue-specific morphogenesis during the development of simple and stratified epithelia. It contributes to the anchoring of desmosomes and hemidesmosomes and modulates signaling through phosphorylation-sensitive filament dynamics. CK7 supports glandular barrier function and secretion. Abnormal CK7 expression is widely used as a diagnostic and prognostic immunohistochemical marker. CK7 expression also correlates with poor differentiation, invasive tumor fronts, tumor emboli, and progression in colorectal and cervical cancers, and is associated with HPV-related transformation, where coordinate expression of CK7 and CK19 in cervical intraepithelial neoplasia or squamocolumnar junction lesions predicts viral replication and integration.

Background

Cytokeratin 7, or CK7, is a type II intermediate filament protein encoded by the KRT7 gene on chromosome 12q12-13. It forms heterotypic pairs with type I keratins such as CK19 to build the cytoskeletal framework vital for maintaining structural integrity in epithelial cells, especially within simple glandular epithelia lining organs like the lung, breast, ovary, biliary tract, pancreas, urothelium, and the ducts and blood vessels of the female genital tract. CK7 features a central alpha-helical rod domain of 310 to 350 amino acids, which shares about 50 to 90 percent sequence identity with other type II keratins and contains four heptad-repeat segments (1A, 1B, 2A, 2B) necessary for coiled-coil dimerization. This rod is flanked by non-helical N-terminal and C-terminal head and tail domains that include V1 and V2 subdomains rich in glycine and serine, contributing to its insolubility and molecular interactions, and conserved H1 and H2 motifs typical of type II chains, enabling the formation of tetramers that further assemble into 10 nm intermediate filaments providing mechanical resilience. CK7 maintain cytoplasmic architecture and withstands mechanical stress in ductal epithelia, while also facilitating cell differentiation, polarity, and tissue-specific morphogenesis during the development of simple and stratified epithelia. It contributes to the anchoring of desmosomes and hemidesmosomes and modulates signaling through phosphorylation-sensitive filament dynamics. CK7 supports glandular barrier function and secretion. Abnormal CK7 expression is widely used as a diagnostic and prognostic immunohistochemical marker. CK7 expression also correlates with poor differentiation, invasive tumor fronts, tumor emboli, and progression in colorectal and cervical cancers, and is associated with HPV-related transformation, where coordinate expression of CK7 and CK19 in cervical intraepithelial neoplasia or squamocolumnar junction lesions predicts viral replication and integration.

References
https://pubmed.ncbi.nlm.nih.gov/29235037/ https://pubmed.ncbi.nlm.nih.gov/38260844/

Reference Table for Selecting PVDF Membrane Pore Size Specifications

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%